8bbs

Publication Abstract from PubMed

Aldo-keto reductase 1C3 (AKR1C3) catalyzes the reduction of androstenedione to testosterone and reduces the effectiveness of chemotherapeutics. AKR1C3 is a target for treatment of breast and prostate cancer and AKR1C3 inhibition could be an effective adjuvant therapy in the context of leukemia and other cancers. In the present study, steroidal bile acid fused tetrazoles were screened for their ability to inhibit AKR1C3. Four C24 bile acids with C-ring fused tetrazoles were moderate to strong AKR1C3 inhibitors (37-88% inhibition), while B-ring fused tetrazoles had no effect on AKR1C3 activity. Based on a fluorescence assay in yeast cells, these four compounds displayed no affinity for estrogen receptor-alpha, or the androgen receptor, suggesting a lack of estrogenic or androgenic effects. A top inhibitor showed specificity for AKR1C3 over AKR1C2, and inhibited AKR1C3 with an IC(50) of approximately 7 muM. The structure of AKR1C3.NADP(+) in complex with this C-ring fused bile acid tetrazole was determined by X-ray crystallography at 1.4 A resolution, revealing that the C24 carboxylate is anchored to the catalytic oxyanion site (H117, Y55); meanwhile the tetrazole interacts with a tryptophan (W227) important for steroid recognition. Molecular docking predicts that all four top AKR1C3 inhibitors bind with nearly identical geometry, suggesting that C-ring bile acid fused tetrazoles represent a new class of AKR1C3 inhibitors.

X-ray structure of human aldo-keto reductase 1C3 in complex with a bile acid fused tetrazole inhibitor: experimental validation, molecular docking and structural analysis.,Marinovic MA, Bekic SS, Kugler M, Brynda J, Skerlova J, Skoric DD, Rezacova P, Petri ET, Celic AS RSC Med Chem. 2022 Dec 1;14(2):341-355. doi: 10.1039/d2md00387b. eCollection 2023 , Feb 22. PMID:36846371^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.